EWA vs IBB
iShares MSCI Australia ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (3.01%).
Side-by-side metrics
| Metric | EWA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.44% |
Dividend yield Trailing 12-month yield. | 3.01% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $1.45B | $9.09B |
YTD return | 8.89% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 0.69 |
P/E ratio | 20.84 | 24.79 |
Last price | $28.26 | $196.62 |
Inception | — | — |
Issuer | iShares | iShares |
EWA top holdings
| BHP.AX | BHP Group Ltd | 14.82% |
| CBA.AX | Commonwealth Bank of Australia | 13.52% |
| WBC.AX | Westpac Banking Corp | 5.91% |
| NAB.AX | National Australia Bank Ltd | 5.70% |
| ANZ.AX | ANZ Group Holdings Ltd | 5.23% |
| WES.AX | Wesfarmers Ltd | 5.04% |
| MQG.AX | Macquarie Group Ltd | 4.45% |
| RIO.AX | Rio Tinto Ltd | 3.15% |
| GMG.AX | Goodman Group | 3.05% |
| CSL.AX | CSL Ltd | 2.73% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.5B in assets under management, an expense ratio of 0.50%, a dividend yield of 3.01%. Its largest holding is BHP Group Ltd (BHP.AX), which represents 14.8% of the portfolio. Real Estate is the fund's largest sector exposure at 5.1%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.